Tema Cardiovascular and Metabolics ETF Rating $29.19 +0.42 (+1.46%) As of 03:42 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.77Holdings in HRTS have an aggregate rating of Moderate Buy based on 650 analyst ratings issued in the past year covering 39 companies (83.6% of the portfolio).HRTS Aggregate Price Target$29.19High Prediction$29.19Average Prediction$29.19Low Prediction$29.19Holdings in HRTS have an aggregate price target of $29.19 and a range of $29.19 to $29.19 covering 39 companies (83.6% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy23 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.59%LLYEli Lilly and Company$811.62+0.4%4.9254 of 5 stars2.76$1,011.37 24.6%21Trending NewsAnalyst Revision4.69%ABTAbbott Laboratories$136.33+0.8%4.947 of 5 stars2.84$142.59 4.6%19Positive News3.91%UNHUnitedHealth Group$318.14+2.4%4.9993 of 5 stars2.60$426.52 34.1%25Trending NewsDividend IncreaseAnalyst DowngradeInsider TradeAnalyst RevisionHigh Trading Volume3.88%RHHBYRoche$41.95+2.1%N/A2.5773.67%BSXBoston Scientific$98.43-1.0%4.5919 of 5 stars3.09$116.00 17.9%22Positive News3.24%VRTXVertex Pharmaceuticals$460.06+1.7%4.6488 of 5 stars2.57$515.04 12.0%30Positive NewsAnalyst Revision3.17%GILDGilead Sciences$112.05+2.5%4.8747 of 5 stars2.78$110.55 -1.3%27Trending NewsOptions VolumeAnalyst Revision3.10%BBIOBridgeBio Pharma$39.65+1.5%4.6256 of 5 stars2.92$57.36 44.7%12Trending NewsAnalyst ForecastInsider TradeAnalyst Revision2.83%CRNXCrinetics Pharmaceuticals$32.17-0.5%3.5575 of 5 stars2.91$74.56 131.8%11Positive NewsAnalyst Revision2.77%MDTMedtronic$88.47+0.5%4.651 of 5 stars2.56$97.00 9.6%16Trending NewsShort Interest ↓2.66%TMOThermo Fisher Scientific$414.85-0.1%4.9764 of 5 stars2.80$605.30 45.9%20Positive News2.45%MRKMerck & Co., Inc.$81.74+1.8%4.9971 of 5 stars2.43$109.19 33.6%21Trending NewsAnalyst Revision2.36%PODDInsulet$303.62+0.5%4.2389 of 5 stars2.82$318.41 4.9%172.24%EWEdwards Lifesciences$75.86+0.5%4.5707 of 5 stars2.40$80.20 5.7%25Positive News2.24%ABBVAbbVie$192.27+0.4%4.7184 of 5 stars2.81$211.29 9.9%27Trending NewsAnalyst ForecastAnalyst Revision2.14%BMYBristol-Myers Squibb$50.68+1.0%4.8597 of 5 stars2.32$58.00 14.4%22Trending NewsAnalyst Revision2.07%REGNRegeneron Pharmaceuticals$521.84+0.6%4.8616 of 5 stars2.85$836.48 60.3%26Analyst ForecastAnalyst Revision2.05%DHRDanaher$204.85+0.1%4.8308 of 5 stars2.80$248.17 21.1%20Positive NewsAnalyst Downgrade1.99%MCKMcKesson$730.39+1.8%4.3901 of 5 stars2.87$694.38 -4.9%15Positive NewsAnalyst ForecastInsider Trade1.94%ALNYAlnylam Pharmaceuticals$304.67+2.0%4.2819 of 5 stars2.77$319.58 4.9%26Positive NewsAnalyst Forecast1.71%AMGNAmgen$297.29+1.9%4.4635 of 5 stars2.38$309.22 4.0%24Positive NewsAnalyst Revision1.60%DXCMDexCom$82.85-0.2%4.7505 of 5 stars2.95$98.32 18.7%211.57%CYTKCytokinetics$33.20+0.3%4.4184 of 5 stars2.93$70.92 113.6%15Analyst ForecastAnalyst Revision1.56%MREOMereo BioPharma Group$2.78+4.9%1.9278 of 5 stars3.25$7.71 177.5%8Positive NewsAnalyst Revision1.37%IONSIonis Pharmaceuticals$35.62-1.6%4.4517 of 5 stars2.65$56.83 59.6%20News CoverageAnalyst Forecast1.35%INSMInsmed$96.88-1.1%3.4779 of 5 stars3.00$104.81 8.2%18Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume1.32%ASNDAscendis Pharma A/S$170.92-0.5%3.5574 of 5 stars3.00$217.73 27.4%15Analyst ForecastAnalyst Revision1.23%MASIMasimo$165.34-1.0%4.1659 of 5 stars2.83$191.60 15.9%61.15%ARWRArrowhead Pharmaceuticals$16.22-3.1%3.6049 of 5 stars2.75$43.71 169.5%8Analyst Revision1.13%VKTXViking Therapeutics$28.58-1.3%4.4091 of 5 stars3.00$87.15 204.9%14News CoverageOptions VolumeAnalyst Revision1.13%GPCRStructure Therapeutics$22.22-2.2%2.4857 of 5 stars3.00$76.50 244.3%7News CoveragePositive NewsAnalyst Revision1.06%MDGLMadrigal Pharmaceuticals$297.21+1.0%4.3388 of 5 stars2.89$420.63 41.5%9Positive NewsAnalyst Revision0.98%AKROAkero Therapeutics$53.56+1.1%3.6374 of 5 stars3.00$82.50 54.0%7Insider TradeOptions Volume0.90%MIRMMirum Pharmaceuticals$49.02+1.2%3.2193 of 5 stars3.17$60.73 23.9%12Analyst Revision0.85%WSTWest Pharmaceutical Services$225.10+0.5%4.7742 of 5 stars3.00$332.50 47.7%8Trending News0.65%SRRKScholar Rock$33.32+0.9%4.4587 of 5 stars3.14$42.67 28.1%7Positive News0.44%RCKTRocket Pharmaceuticals$3.07+1.3%4.9578 of 5 stars2.41$19.57 537.5%17Trending NewsAnalyst Revision0.32%NTLAIntellia Therapeutics$8.35-0.2%4.5877 of 5 stars2.67$34.95 318.6%21Analyst Revision0.32%MTSRMetsera$34.58+4.6%N/A3.00$50.00 44.6%4News CoverageAnalyst ForecastAnalyst RevisionGap Up This page (NASDAQ:HRTS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTS Stock Free HRTS Stock Alerts